Extracellular vesicles from bone marrow-derived mesenchymal stem cells improve survival from lethal hepatic failure in mice

Hiroaki Haga, Irene K. Yan, Kenji Takahashi, Akiko Matsuda, Tushar C Patel

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Stem cell-based therapies have potential for treatment of liver injury by contributing to regenerative responses, through functional tissue replacement or paracrine effects. The release of extracellular vesicles (EV) from cells has been implicated in intercellular communication, and may contribute to beneficial paracrine effects of stem cell-based therapies. Therapeutic effects of bone-marrow derived mesenchymal stem cells (MSC) and vesicles released by these cells were examined in a lethal murine model of hepatic failure induced by D-galactosamine/tumor necrosis factor-α (TNF-α). Systemically administered EV derived from MSC accumulated within the injured liver following systemic administration, reduced hepatic injury, and modulated cytokine expression. Moreover, survival was dramatically increased by EV derived from either murine or human MSC. Similar results were observed with the use of cryopreserved mMSC-EV after 3 months. Y-RNA-1 was identified as a highly enriched noncoding RNA within hMSC-EV compared to cells of origin. Moreover, siRNA mediated knockdown of Y-RNA-1 reduced the protective effects of MSC-EV on TNF-α/ActD-mediated hepatocyte apoptosis in vitro. These data support a critical role for MSC-derived EV in mediating reparative responses following hepatic injury, and provide compelling evidence to support the therapeutic use of MSC-derived EV in fulminant hepatic failure.

Original languageEnglish (US)
Pages (from-to)1262-1272
Number of pages11
JournalStem cells translational medicine
Volume6
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Liver Failure
Mesenchymal Stromal Cells
Cell Survival
Bone Marrow
Liver
Therapeutic Uses
Cell- and Tissue-Based Therapy
Wounds and Injuries
Stem Cells
Tumor Necrosis Factor-alpha
RNA
Galactosamine
Untranslated RNA
Acute Liver Failure
Extracellular Vesicles
Small Interfering RNA
Hepatocytes
Apoptosis
Cytokines
Survival

Keywords

  • Apoptosis
  • Cytokines
  • Extracellular vesicles
  • Fulminant hepatic failure
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Extracellular vesicles from bone marrow-derived mesenchymal stem cells improve survival from lethal hepatic failure in mice. / Haga, Hiroaki; Yan, Irene K.; Takahashi, Kenji; Matsuda, Akiko; Patel, Tushar C.

In: Stem cells translational medicine, Vol. 6, No. 4, 01.04.2017, p. 1262-1272.

Research output: Contribution to journalArticle

@article{734d9bdaa8624781bc4c08c089f34718,
title = "Extracellular vesicles from bone marrow-derived mesenchymal stem cells improve survival from lethal hepatic failure in mice",
abstract = "Stem cell-based therapies have potential for treatment of liver injury by contributing to regenerative responses, through functional tissue replacement or paracrine effects. The release of extracellular vesicles (EV) from cells has been implicated in intercellular communication, and may contribute to beneficial paracrine effects of stem cell-based therapies. Therapeutic effects of bone-marrow derived mesenchymal stem cells (MSC) and vesicles released by these cells were examined in a lethal murine model of hepatic failure induced by D-galactosamine/tumor necrosis factor-α (TNF-α). Systemically administered EV derived from MSC accumulated within the injured liver following systemic administration, reduced hepatic injury, and modulated cytokine expression. Moreover, survival was dramatically increased by EV derived from either murine or human MSC. Similar results were observed with the use of cryopreserved mMSC-EV after 3 months. Y-RNA-1 was identified as a highly enriched noncoding RNA within hMSC-EV compared to cells of origin. Moreover, siRNA mediated knockdown of Y-RNA-1 reduced the protective effects of MSC-EV on TNF-α/ActD-mediated hepatocyte apoptosis in vitro. These data support a critical role for MSC-derived EV in mediating reparative responses following hepatic injury, and provide compelling evidence to support the therapeutic use of MSC-derived EV in fulminant hepatic failure.",
keywords = "Apoptosis, Cytokines, Extracellular vesicles, Fulminant hepatic failure, Tumor necrosis factor",
author = "Hiroaki Haga and Yan, {Irene K.} and Kenji Takahashi and Akiko Matsuda and Patel, {Tushar C}",
year = "2017",
month = "4",
day = "1",
doi = "10.1002/sctm.16-0226",
language = "English (US)",
volume = "6",
pages = "1262--1272",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "4",

}

TY - JOUR

T1 - Extracellular vesicles from bone marrow-derived mesenchymal stem cells improve survival from lethal hepatic failure in mice

AU - Haga, Hiroaki

AU - Yan, Irene K.

AU - Takahashi, Kenji

AU - Matsuda, Akiko

AU - Patel, Tushar C

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Stem cell-based therapies have potential for treatment of liver injury by contributing to regenerative responses, through functional tissue replacement or paracrine effects. The release of extracellular vesicles (EV) from cells has been implicated in intercellular communication, and may contribute to beneficial paracrine effects of stem cell-based therapies. Therapeutic effects of bone-marrow derived mesenchymal stem cells (MSC) and vesicles released by these cells were examined in a lethal murine model of hepatic failure induced by D-galactosamine/tumor necrosis factor-α (TNF-α). Systemically administered EV derived from MSC accumulated within the injured liver following systemic administration, reduced hepatic injury, and modulated cytokine expression. Moreover, survival was dramatically increased by EV derived from either murine or human MSC. Similar results were observed with the use of cryopreserved mMSC-EV after 3 months. Y-RNA-1 was identified as a highly enriched noncoding RNA within hMSC-EV compared to cells of origin. Moreover, siRNA mediated knockdown of Y-RNA-1 reduced the protective effects of MSC-EV on TNF-α/ActD-mediated hepatocyte apoptosis in vitro. These data support a critical role for MSC-derived EV in mediating reparative responses following hepatic injury, and provide compelling evidence to support the therapeutic use of MSC-derived EV in fulminant hepatic failure.

AB - Stem cell-based therapies have potential for treatment of liver injury by contributing to regenerative responses, through functional tissue replacement or paracrine effects. The release of extracellular vesicles (EV) from cells has been implicated in intercellular communication, and may contribute to beneficial paracrine effects of stem cell-based therapies. Therapeutic effects of bone-marrow derived mesenchymal stem cells (MSC) and vesicles released by these cells were examined in a lethal murine model of hepatic failure induced by D-galactosamine/tumor necrosis factor-α (TNF-α). Systemically administered EV derived from MSC accumulated within the injured liver following systemic administration, reduced hepatic injury, and modulated cytokine expression. Moreover, survival was dramatically increased by EV derived from either murine or human MSC. Similar results were observed with the use of cryopreserved mMSC-EV after 3 months. Y-RNA-1 was identified as a highly enriched noncoding RNA within hMSC-EV compared to cells of origin. Moreover, siRNA mediated knockdown of Y-RNA-1 reduced the protective effects of MSC-EV on TNF-α/ActD-mediated hepatocyte apoptosis in vitro. These data support a critical role for MSC-derived EV in mediating reparative responses following hepatic injury, and provide compelling evidence to support the therapeutic use of MSC-derived EV in fulminant hepatic failure.

KW - Apoptosis

KW - Cytokines

KW - Extracellular vesicles

KW - Fulminant hepatic failure

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=85017544552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017544552&partnerID=8YFLogxK

U2 - 10.1002/sctm.16-0226

DO - 10.1002/sctm.16-0226

M3 - Article

VL - 6

SP - 1262

EP - 1272

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 4

ER -